Sirolimus as a second-line treatment for Graves’ orbitopathy

OBJECTIVES: A beneficial effect of sirolimus in Graves’ orbitopathy (GO) was reported, suggesting a possible use in clinical practice. We conducted an observational, single-centre, no-profit, clinical study to investigate the efficacy of sirolimus as a second-line treatment for moderate-to-severe, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanzolla, G., Maglionico, M. N., Comi, S., Menconi, F., Piaggi, P., Posarelli, C., Figus, M., Marcocci, C., Marinò, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525329/
https://www.ncbi.nlm.nih.gov/pubmed/35831587
http://dx.doi.org/10.1007/s40618-022-01862-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525329/
https://www.ncbi.nlm.nih.gov/pubmed/35831587
http://dx.doi.org/10.1007/s40618-022-01862-y

Ejemplares similares